Evidence map›Paper›PMID 40682697›Full record

ArticleInternational urogynecology journal2025

Evaluation of the Safety of Virtual Visits After In-Clinic Botox® Injection: A Quality Improvement Study.

K Marie Douglass, Katharina Laus, Samantha DeAndrade, Taylor Whitaker, Tajnoos Yazdany, Christina Truong

Abstract read
PubMed Publisher
In one paragraph

Article in International urogynecology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

K Marie DouglassDivision of Urogynecology & Reconstructive Pelvic Surgery, Department of OB/GYN, Harbor-UCLA Medical Center, 1000 W Carson Street, Torrance, CA, 90052, USA. KDouglass2@dhs.lacounty.gov.ORCID 0000-0002-1987-8409
Katharina LausDivision of Urogynecology & Reconstructive Pelvic Surgery, Department of OB/GYN, Kaiser Permanente Dublin Medical Center, Dublin, CA, 94568, USA.
Samantha DeAndradeDivision of Urogynecology & Reconstructive Pelvic Surgery, Department of OB/GYN, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA.
Taylor WhitakerDivision of Urogynecology & Reconstructive Pelvic Surgery, Department of OB/GYN, Harbor-UCLA Medical Center, 1000 W Carson Street, Torrance, CA, 90052, USA.
Tajnoos YazdanyDivision of Urogynecology & Reconstructive Pelvic Surgery, Department of OB/GYN, Harbor-UCLA Medical Center, 1000 W Carson Street, Torrance, CA, 90052, USA.
Christina TruongDivision of Urogynecology & Reconstructive Pelvic Surgery, Department of OB/GYN, Harbor-UCLA Medical Center, 1000 W Carson Street, Torrance, CA, 90052, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction and hypothesisVirtual visits can be performed after in-clinic injection of Botox®, but data are lacking on the safety of these visits. The aim of this study was to evaluate the effects of a protocol change from in-person to virtual post-procedure visits after in-clinic injection of Botox®.

methodsThis was a quality improvement study that took place at a safety-net hospital. Initially, all patients undergoing Botox® injection for idiopathic overactive bladder were scheduled for a 2-week in-person assessment after their procedure. Beginning in January 2023, patients were instead scheduled for a 2-week phone visit where they were screened using standardized and validated questionnaires and asked to present for in-person assessment if they expressed worsening or concerning symptoms. Demographic variables, subjective improvement, need for in-person assessment, and rates of urinary tract infection and retention were compared between groups.

resultsFifty-seven patients in the in-person-visit group and 60 in the phone-visit group were included. There was no difference in subjective improvement, symptoms of dysuria or incomplete emptying, or rates of urinary tract infection or retention between groups. Twenty-eight percent of patients who had phone visits were asked to return in-person, although this did not correspond with a higher rate of complications. The phone-visit group had a 68.3% reduction in face-to-face assessments overall when compared with the in-person group.

conclusionsPost-procedure phone visits are safe and feasible to perform after in-clinic Botox® injection, and are not associated with an increased risk of complications.

Indexed as

Botulinum Toxins, Type ANeuromuscular AgentsTelemedicineUrinary Bladder, OveractiveAdultAgedFemaleHumansMiddle AgedQuality ImprovementUrinary Tract InfectionsBotulinum Toxins, Type ANeuromuscular AgentsOnabotulinumtoxinaOveractive bladderTelemedicine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.